Alterity Therapeutics Files 6-K on Shareholder Holdings

Ticker: PRNAF · Form: 6-K · Filed: May 23, 2025 · CIK: 1131343

Alterity Therapeutics Ltd 6-K Filing Summary
FieldDetail
CompanyAlterity Therapeutics Ltd (PRNAF)
Form Type6-K
Filed DateMay 23, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: shareholder-update, disclosure, foreign-issuer

Related Tickers: ATHE

TL;DR

Alterity Therapeutics (ATHE) filed a 6-K for May 2025, updating substantial holding info - check for shareholder shifts.

AI Summary

Alterity Therapeutics Limited filed a Form 6-K on May 23, 2025, to report a change in substantial holding. This filing is incorporated by reference into several of their existing registration statements on Form S-8 and Form F-3. The company, formerly known as PRANA BIOTECHNOLOGY LTD, is a development stage enterprise based in Melbourne, Australia.

Why It Matters

This filing provides an update on significant changes in the ownership structure of Alterity Therapeutics, which could impact investor sentiment and stock trading.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of changes in substantial holdings and does not indicate any new material risks for the company.

Key Players & Entities

  • Alterity Therapeutics Limited (company) — Registrant
  • PRANA BIOTECHNOLOGY LTD (company) — Former Company Name
  • May 2025 (date) — Reporting Period
  • 20250523 (date) — Filing Date
  • Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (address) — Principal Executive Office

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K filing is to report a change in substantial holding for Alterity Therapeutics Limited.

When was this Form 6-K filed?

This Form 6-K was filed on May 23, 2025.

What is Alterity Therapeutics Limited's former company name?

Alterity Therapeutics Limited's former company name was PRANA BIOTECHNOLOGY LTD.

Which registration statements is this 6-K incorporated into?

This Form 6-K is incorporated by reference into Alterity Therapeutics' Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).

Where is Alterity Therapeutics Limited's principal executive office located?

Alterity Therapeutics Limited's principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on May 23, 2025 regarding ALTERITY THERAPEUTICS LTD (PRNAF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.